Search
Alclofenac
go.drugbank.com/drugs/DB13167ApprovedWithdrawnAlclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth hormone (GH) and decreases the pro...
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.
Products: Nu-trihexyphenidylBenzethonium
go.drugbank.com/drugs/DB11125ApprovedBenzethonium is a synthetic quaternary ammonium salt with surfactant, antiseptic, and broad spectrum antimicrobial properties. Its salt form, benzethonium chloride, is primarily used as a skin disinfectant at concentrations of 0.1-0.2 %,...
Mixtures: Dr. NumbProducts: Handi-San, Quik SanIvacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigational, an ion channel involved in the transport of chloride and sodium ions across cell membranes. … [L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein
Synonyms: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamideAutologous peripheral blood-derived CD34+ cells
go.drugbank.com/drugs/DB16367ApprovedInvestigationalAutologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. It is also a cell therapy being investigated by Caladrius Biosciences in th...
Ambenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnAmbenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.
Imetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigational[erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigationalTaletrectinib is an orally available small molecule kinase inhibitor.
Cefazolin
go.drugbank.com/drugs/DB01327ApprovedInvestigationalA semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.